Abstract
The current outbreak of novel COVID-19 challenges the development of an efficient treatment plan as soon as possible. Several promising treatment options stand out as potential therapy of COVID-19, including plasma-derived drugs, monoclonal antibodies, antivirals, antimalarial, cell therapy, and corticosteroids. Dexamethasone an approved corticosteroid medication, acting as an anti-inflammatory and immunosuppressant agent. In the current pandemic, dexamethasone is declared a “major development” in the fight against COVID-19. Steroidal dexamethasone was presented as the recent advancement that significantly reduces the mortality rate among severe COVID-19 cases. This review summarizes the preliminary opinion about the dexamethasone outbreak, therapeutic potential, risks, and strategies during the COVID-19 pandemic.
【저자키워드】 Corticosteroid, Dexamethasone, SARS-CoV-2, COVID-19 therapeutics, acute respiratory distress syndrome (ARDS), Immunosuppressant, 【초록키워드】 COVID-19, Treatment, Corticosteroids, pandemic, therapy, severe COVID-19, Anti-inflammatory, antivirals, COVID-19 pandemic, drugs, monoclonal antibodies, antimalarial, outbreak, mortality rate, medication, therapeutic potential, potential therapy, Cell, significantly, approved, reduce, acting, 【제목키워드】 COVID-19 pandemic,